CoChat

Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode

Open access
Keating, Dolores, McWilliams, Stephen, Schneider, Ian, Hynes, Caroline, Cousins, Gráinne, Strawbridge, Judith, Clarke, Mary · 2017 · BMJ Open
Cited by 130

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Objectives: Clinical practice guidelines (CPGs) support the translation of research evidence into clinical practice. Key health questions in CPGs ensure that recommendations will be applicable to the clinical context in which the guideline is used. The objectives of this study were to identify CPGs for the pharmacological treatment of first-episode schizophrenia; assess the quality of these guidelines using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument; and compare recommendations in relation to the key health questions that are relevant to the pharmacological treatment of first-episode schizophrenia. Methods: A multidisciplinary group identified key health questions that are relevant to the pharmacological treatment of first-episode schizophrenia. The MEDLINE and EMBASE databases, websites of professional organisations and international guideline repositories, were searched for CPGs that met the inclusion criteria. The AGREE II instrument was applied by three raters and data were extracted from the guidelines in relation to the key health questions. Results: In total, 3299 records were screened. 10 guidelines met the inclusion criteria. 3 guidelines scored well across all domains. Recommendations varied in specificity. Side effect concerns, rather than comparative efficacy benefits, were a key consideration in antipsychotic choice. Antipsychotic medication is recommended for maintenance of remission following a first episode of schizophrenia but there is a paucity of evidence to guide duration of treatment. Clozapine is universally regarded as the medication of choice for treatment resistance. There is less evidence to guide care for those who do not respond to clozapine. Conclusions: An individual's experience of using antipsychotic medication for the initial treatment of first-episode schizophrenia may have implications for future engagement, adherence and outcome. While guidelines of good quality exist to assist in medicines optimisation, the evidence base required to answer key health questions relevant to the pharmacological treatment of first-episode schizophrenia is limited.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2016-013881

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 50

  1. Cowen P , Harrison P , Burns T . Shorter Oxford textbook of psychiatry. Oxford University Press, 2012. · DOI
  2. 10.1192/bjp.187.48.s116 · DOI · Paper page
  3. 10.1093/schbul/sbi032 · DOI
  4. 10.1016/j.eurpsy.2004.06.031 · DOI · Paper page
  5. Graham R , Mancher M , Wolman DM , et al . Clinical practice guidelines we can trust. National Academies Press, 2011. · DOI · Paper page
  6. 10.1192/bjp.bp.112.112383 · doi:10.1192/bjp.bp.112.112383
  7. 10.1111/bdi.12128 · DOI
  8. 10.1192/bjp.187.3.248 · DOI · Paper page
  9. 10.3109/09540261.2011.606801 · DOI
  10. Castellani, 2015, Rigour of development of clinical practice guidelines for the pharmacological treatment of bipolar disorder: systematic review, J Affect Disord, 174, 45, 10.1016/j.jad.2014.11.032 · DOI
  11. 10.1136/bmjopen-2015-009189 · DOI
  12. Moore, 2011, Schizophrenia treatment guidelines in the United States, Clin Schizophr Relat Psychoses, 5, 40, 10.3371/CSRP.5.1.6 · DOI
  13. 10.3109/15622975.2012.696143 · DOI · Paper page
  14. 10.3109/15622975.2012.739708 · DOI · Paper page
  15. Hasan, 2015, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation, World J Biol Psychiatry, 16, 142, 10.3109/15622975.2015.1009163 · DOI · Paper page
  16. 10.1093/schbul/sbp116 · DOI · Paper page
  17. Barnes, 2011, Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology, J Psychopharmacol (Oxford), 25, 567, 10.1177/0269881110391123 · DOI · Paper page
  18. Osser, 2013, The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia, Harv Rev Psychiatry, 21, 18, 10.1097/HRP.0b013e31827fd915 · DOI
  19. 10.1016/S0140-6736(08)60486-9 · DOI · Paper page
  20. 10.1097/YCO.0b013e32830eb6b4 · DOI · Paper page
  21. 10.1136/bmj.g3725 · DOI · Paper page
  22. Mavridis, 2016, Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant, J Clin Epidemiol, 69, 161, 10.1016/j.jclinepi.2015.05.027 · DOI
  23. Samalin, 2013, Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?, Compr Psychiatry, 54, 309, 10.1016/j.comppsych.2012.10.001 · DOI
  24. 10.1016/j.schres.2011.04.006 · DOI
  25. 10.1016/j.schres.2013.07.031 · DOI · Paper page
  26. 10.1016/j.schres.2012.08.013 · DOI
  27. 10.1016/j.schres.2016.02.034 · DOI
  28. 10.1176/appi.ajp.2014.14111465 · DOI
  29. Hynes, 2015, Glasgow antipsychotic side-effects scale for clozapine—development and validation of a clozapine-specific side-effects scale, Schizophr Res, 168, 505, 10.1016/j.schres.2015.07.052 · DOI
  30. Haro, 2014, Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship?, Psychiatry Res, 220, 163, 10.1016/j.psychres.2014.07.034 · doi:10.1016/j.psychres.2014.07.034
  31. 10.1176/appi.ajp.2008.08050756 · DOI · Paper page
  32. Karson, 2016, Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review, Neuropsychiatr Dis Treat, 12, 57, 10.2147/NDT.S96392 · DOI
  33. 10.1176/appi.ajp.2012.12060778 · DOI
  34. Lieberman, 2003, Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine, Neuropsychopharmacology, 28, 995, 10.1038/sj.npp.1300157 · DOI · Paper page
  35. 10.4088/JCP.09m05785yel · DOI · Paper page
  36. 10.1093/schbul/sbp129 · DOI · Paper page
  37. Heres, 2014, Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics, Eur Psychiatry, 29, 1409, 10.1016/S0924-9338(14)70001-X · DOI · Paper page
  38. 10.1093/schbul/18.3.515 · DOI · Paper page
  39. 10.1001/archpsyc.63.10.1079 · DOI · Paper page
  40. Stroup, 2014, What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?, J Clin Psychiatry, 75, 1261, 10.4088/JCP.14com09518 · DOI
  41. Samara, 2016, Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis, JAMA psychiatry, 73, 199, 10.1001/jamapsychiatry.2015.2955 · DOI · Paper page
  42. 10.1186/1471-244X-10-8 · DOI · Paper page
  43. 10.1093/schbul/sbu065 · DOI
  44. 10.1192/bjp.bp.111.105833 · DOI · Paper page
  45. Girlanda F , Fiedler I , Becker T , et al . The evidence–practice gap in specialist mental healthcare: systematic review and meta-analysis of guideline implementation studies. Br J Psychiatry 2016. doi:10.1192/bjp.bp.115.179093 · DOI · Paper page
  46. 10.1176/appi.ajp.2014.13101355 · DOI · Paper page
  47. 10.4088/JCP.v64n0107 · DOI · Paper page
  48. Üçok, 2015, Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia, Int Clin Psychopharmacol, 30, 290, 10.1097/YIC.0000000000000086 · DOI
  49. 10.1097/JCP.0b013e318267b3cd · DOI · Paper page
  50. Campsall, 2016, Financial relationships between organizations that produce clinical practice guidelines and the biomedical industry: a cross-sectional study, PLoS Med, 13, e1002029, 10.1371/journal.pmed.1002029 · DOI

Cited by

See all 130

Metadata

Authors
Keating, D., McWilliams, S., Schneider, I., Hynes, C., Cousins, G., Strawbridge, J., & Clarke, M.
Venue
BMJ Open
Publisher
BMJ
Published
2017-01
Volume
7
Issue
1
Pages
e013881
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2567911914
Cited by
130
References
10
FWCI
2.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. https://app.cochat.ai/papers/10.1136/bmjopen-2016-013881
The paper
Keating, D., McWilliams, S., Schneider, I., Hynes, C., Cousins, G., Strawbridge, J., & Clarke, M. (2017). Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. https://doi.org/10.1136/bmjopen-2016-013881

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.